Gina Quinlan

Who they are

Gina Quinlan is Associate Director of Training at AbbVie — she came up through clinical informatics at UPMC, where she managed ambulatory systems before moving into pharma training.

Person

Gina's career tracks a clear path from clinical operations into pharmaceutical training. She spent time at UPMC as Manager of Clinical Ambulatory Informatics — a role sitting at the intersection of nursing practice and health IT — before moving into the pharma industry at AbbVie, where she now holds the Associate Director of Training title. Based in Indianapolis, her content themes cluster around clinical nurse education, oncology, patient engagement, and ovarian cancer support, suggesting her training work touches therapeutic areas with real patient-facing weight. The through-line is clinical expertise applied to education: each step moves further from bedside systems and closer to structured learning design. Possibly — her earlier clinical background informs how she designs training for complex therapeutic areas like oncology and immunology, where scientific fluency matters as much as instructional technique. She posts occasionally on LinkedIn, though no standalone publication or blog is evident from available signals.

Company

AbbVie's most recent move — announced in June 2026 — is a licensing deal with FutureGen for FG-M701, a TL1A inhibitor, for $150 million upfront, reinforcing its immunology pipeline. That follows a busy first half of 2026: AbbVie reported Q1 revenue of $15 billion and adjusted EPS of $2.65, beating expectations, and received a Buy upgrade from Bank of America citing durable growth prospects for Skyrizi into the mid-2030s. On the manufacturing side, AbbVie announced a $1.4 billion campus in Durham, North Carolina in January 2026 and acquired an Arizona facility for over $175 million the same month, both part of a $10 billion domestic manufacturing commitment tied to a deal with the Trump administration that exchanged tariff exemptions for lower Medicaid prices. The company employs approximately 60,360 people as of April 2026, with CEO Robert Michael leading it through this period of pipeline expansion and U.S. investment.

Market

AbbVie competes across immunology, oncology, neuroscience, and aesthetics against Johnson & Johnson, Pfizer, Eli Lilly, Amgen, Regeneron, and a cluster of other large-cap pharma players. Its $26.68 billion immunology revenue in 2024 gives it a leading position in that category, with Skyrizi and Rinvoq now carrying the load that Humira held before biosimilar entry in 2023. Pricing reform pressure from the U.S. government and biosimilar competition are the two structural headwinds shaping AbbVie's strategy, driving both its domestic manufacturing push and its hybrid R&D model combining internal research with over 250 external partnerships.

How they likely show up

Career path from clinical informatics (UPMC) to pharma training (AbbVie) → likely bridges technical/clinical content with structured adult learning, comfortable translating complex material for non-expert audiences.
Content themes include oncology and ovarian cancer support → probably brings patient-outcome orientation to training design, not just compliance or process focus.
Role type pattern is 'specialist' → likely operates as a deep subject-matter contributor rather than a broad generalist manager; expects precision in the topics she engages with.
Possibly — move from health system (UPMC) to pharma (AbbVie) suggests comfort operating in highly regulated, compliance-heavy environments where documentation and process rigor are baseline expectations.
Occasional public writing signal on LinkedIn → not a prolific public voice, but willing to share perspectives when the topic warrants it; unlikely to be drawn in by shallow engagement.

Conversation tips

→ Anchor conversation in clinical context — her background is in clinical informatics and nurse education, so she'll engage more readily when the discussion connects to patient-facing or HCP-facing outcomes.
→ Ask about the translation challenge: moving from health-system training (UPMC's ambulatory environment) to pharma training (AbbVie's therapeutic areas) is a real career pivot, and she'll have a clear story about what changed.
→ Reference AbbVie's oncology pipeline specifically — her content themes include oncology and ovarian cancer support, so she's likely close to those therapeutic areas professionally.
→ Don't assume she's purely an instructional designer — her clinical informatics background means she understands systems and workflows, not just curriculum.

Toolbox

Openers

Open on the clinical-to-pharma transition — she moved from managing ambulatory informatics systems at UPMC to leading training at AbbVie, and that's an unusual path worth unpacking: what from health IT carried over into pharma education?
Reference AbbVie's oncology pipeline momentum — with the ImmunoGen acquisition and the Neomorph molecular glue partnership, the oncology portfolio is growing fast, and her content themes suggest she's close to that therapeutic area.
Mention AbbVie's domestic manufacturing expansion — the Durham campus, the Arizona facility acquisition, and the $10 billion U.S. commitment represent a major organizational scaling moment that likely has training implications across the 60,360-person workforce.

Discovery questions

How does training design change when you're preparing teams for a new therapeutic area — say, moving from immunology into oncology or metabolic disease — versus updating an established program?
Moving from clinical informatics at a health system like UPMC into pharma training at AbbVie is a real context shift — what did you find translated directly, and what did you have to rebuild from scratch?
With AbbVie scaling manufacturing significantly in the U.S. — new sites in Durham and Arizona, thousands of new hires planned — how does that kind of workforce growth change what the training function needs to deliver?

Avoid

Don't treat her as a generic L&D professional — her clinical informatics and oncology background means she'll disengage quickly if the conversation stays at the level of generic instructional design frameworks without clinical or scientific grounding.

Make it yours